Gilead must face pay-for-delay suit
Sundry Photography / Shutterstock.com
Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, MacroGenics, CD123, blood cancers, licensing, royalties, big pharma